000299547 001__ 299547
000299547 005__ 20250515140519.0
000299547 0247_ $$2doi$$a10.1007/s10865-025-00559-w
000299547 0247_ $$2pmid$$apmid:40042752
000299547 0247_ $$2ISSN$$a0160-7715
000299547 0247_ $$2ISSN$$a1573-3521
000299547 037__ $$aDKFZ-2025-00491
000299547 041__ $$aEnglish
000299547 082__ $$a610
000299547 1001_ $$00000-0001-7679-3658$$aMeissner, Valentin H$$b0
000299547 245__ $$aWorry about prostate cancer and risk perception among middle-aged men: results from the PROBASE trial.
000299547 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V.$$c2025
000299547 3367_ $$2DRIVER$$aarticle
000299547 3367_ $$2DataCite$$aOutput Types/Journal article
000299547 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1747310668_1549
000299547 3367_ $$2BibTeX$$aARTICLE
000299547 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000299547 3367_ $$00$$2EndNote$$aJournal Article
000299547 500__ $$a2025 Jun;48(3):464-477
000299547 520__ $$aCancer worry and risk perception are relevant psychological factors that influence preventive health behaviors. Therefore, a thorough understanding of the factors that impact their occurrence and manifestation is critical. The objective of this study was to assess prevalence and factors associated with worry about prostate cancer (PCa) and absolute/comparative risk perception in a community-based sample of 45-year-old men. Data were collected within the German PCa screening trial PROBASE. Variables were assessed by self-report questionnaires and a clinical interview. Worry about PCa and absolute/comparative risk perception were assessed each on a 5-point-Likert scale. Multivariable logistic regression was used to identify factors associated with the outcomes of interest. Data were available for 33,476 (72.0%) of 46,495 men at enrollment. 7.3% had sometimes/(very) often worry about PCa. 3.7% and 9.9% perceived their absolute risk and comparative risk as somewhat high/very high and somewhat higher/much higher, respectively. 18.8% reported a positive PCa family history. Important factors of worry about PCa, absolute risk perception, and comparative risk perception were lower urinary tract symptoms (LUTS) (OR 3.00, 95% CI 2.63-3.42; OR 2.09, CI 1.71-2.56; OR 2.41, CI 2.10-2.76) and a positive PCa family history (OR 2.35, CI 2.08-2.65; OR 15.13, CI 12.73-17.97; OR 9.69, CI 8.76-10.72). A positive history of urological (OR 3.85, CI 2.63-5.63) and non-urological cancers (OR 1.97, CI 1.52-2.54) were associated with a higher comparative risk perception. In conclusion, worry about PCa and risk perception are influenced by non-cancer-related symptoms as well as by a positive PCa family history. These findings need to be addressed in risk communication with patients.
000299547 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000299547 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000299547 650_7 $$2Other$$aAbsolute risk perception
000299547 650_7 $$2Other$$aCancer worry
000299547 650_7 $$2Other$$aComparative risk perception
000299547 650_7 $$2Other$$aFamily history
000299547 650_7 $$2Other$$aLower urinary tract symptoms
000299547 650_7 $$2Other$$aProstate cancer
000299547 7001_ $$aDinkel, Andreas$$b1
000299547 7001_ $$aKron, Martina$$b2
000299547 7001_ $$aSchiele, Stefan$$b3
000299547 7001_ $$aJahnen, Matthias$$b4
000299547 7001_ $$aLakes, Jale$$b5
000299547 7001_ $$aRadtke, Jan Philipp$$b6
000299547 7001_ $$aKuczyk, Markus A$$b7
000299547 7001_ $$aHarke, Nina N$$b8
000299547 7001_ $$aDebus, Jürgen$$b9
000299547 7001_ $$aFink, Christoph A$$b10
000299547 7001_ $$aAntoch, Gerald$$b11
000299547 7001_ $$aSchimmöller, Lars$$b12
000299547 7001_ $$aKristiansen, Glen$$b13
000299547 7001_ $$0P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315$$aKrilaviciute, Agne$$b14
000299547 7001_ $$0P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aSeibold, Petra$$b15
000299547 7001_ $$0P:(DE-He78)6b04712f3afe72044d496a25505cb1ea$$aBehrens, Sabine$$b16
000299547 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b17
000299547 7001_ $$aArsov, Christian$$b18
000299547 7001_ $$0P:(DE-HGF)0$$aHadaschik, Boris$$b19
000299547 7001_ $$0P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab$$aBecker, Nikolaus$$b20
000299547 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b21
000299547 7001_ $$0P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aAlbers, Peter$$b22
000299547 7001_ $$aGschwend, Jürgen E$$b23
000299547 7001_ $$aHerkommer, Kathleen$$b24
000299547 773__ $$0PERI:(DE-600)2016730-1$$a10.1007/s10865-025-00559-w$$n3$$p464-477$$tJournal of behavioral medicine$$v48$$x0160-7715$$y2025
000299547 909CO $$ooai:inrepo02.dkfz.de:299547$$pVDB
000299547 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000299547 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000299547 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b04712f3afe72044d496a25505cb1ea$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000299547 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000299547 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000299547 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000299547 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000299547 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000299547 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000299547 9141_ $$y2025
000299547 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-13$$wger
000299547 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-13$$wger
000299547 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-13$$wger
000299547 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-13
000299547 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-13
000299547 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-13
000299547 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-13
000299547 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-13
000299547 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences$$d2024-12-13
000299547 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-13
000299547 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index$$d2024-12-13
000299547 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ BEHAV MED : 2022$$d2024-12-13
000299547 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-13
000299547 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-13
000299547 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-13
000299547 9201_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000299547 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x1
000299547 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x2
000299547 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x3
000299547 980__ $$ajournal
000299547 980__ $$aVDB
000299547 980__ $$aI:(DE-He78)C130-20160331
000299547 980__ $$aI:(DE-He78)C020-20160331
000299547 980__ $$aI:(DE-He78)C060-20160331
000299547 980__ $$aI:(DE-He78)ED01-20160331
000299547 980__ $$aUNRESTRICTED